Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children with CF (6-11 Years)
NCT03691779Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2018
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label trial of elexacaftor in cystic fibrosis (CF) (2 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration at Day 15, Observed Pre-dose Plasma Concentration at Day 15 and 2 more. Started Oct 2018; status: completed.
02
Drugs
elexacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03691779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691779.